Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Pulmonary Embolism Blood Tests Reduce Radiation Exposure

By HospiMedica International staff writers
Posted on 24 Dec 2019
A new study suggests that D-dimer blood tests can help rule out pulmonary embolism (PE), reducing the need for a diagnostic computerized tomography (CT) scan.

Researchers at McMaster University (Hamilton, ON, Canada), the University of Alberta (Edmonton, Canada), McGill University (Montreal, Canada), and other institutions conducted a prospective study involving 2,017 adult (average age 52 years, 66% female), of whom 7.4% had PE on initial diagnostic testing. More...
PE was considered to be ruled out without further testing in outpatients with a low clinical pretest probability (C-PTP) and a D-dimer level of less than 1000 ng per milliliter, or with a moderate C-PTP and a D-dimer level of less than 500 ng per milliliter.

All other suspected patients underwent chest imaging (usually CT pulmonary angiography); if PE was not diagnosed, the patients did not receive anticoagulant therapy. All patients were followed for 3 months to detect venous thromboembolism (VTE). The results revealed that none of patients who were ruled out based on C-PTP and d-dimer levels had VTE at follow-up. Of 1,863 patients who did not receive a diagnosis of PE initially, and did not receive anticoagulant therapy, one patient had VTE. The study was published on November 27, 2019, in the New England Journal of Medicine (NEJM).

“When a physician is concerned that PE may be present, chest imaging with CT pulmonary angiography is usually done in half of these patients. We wanted to find a way to reduce the number of CT scans that need to be done,” concluded lead author Professor Clive Kearon, MB, PhD, of McMaster University. “Our diagnostic strategy resulted in the use of chest imaging in 34.3% of patients, whereas a strategy in which PE is considered to be ruled out with a low C-PTP and a d-dimer level of less than 500 ng per milliliter would result in the use of chest imaging in 51.9%. This way of using D-dimer testing and clinical assessment reduced the need for CT scanning by one-third.”

D-dimer is a fibrin degradation product. It is so named because it contains two D fragments of the fibrin protein joined by a cross-link. Since its introduction in the 1990s, it has become an important test for patients with suspected thrombotic disorders. While a negative result practically rules out thrombosis, a positive result can indicate thrombosis, but does not rule out other potential causes. Its main use, therefore, is to exclude thromboembolic disease where the probability is low.

Related Links:
McMaster University
University of Alberta
McGill University



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.